1. Academic Validation
  2. The Effectiveness of Myo-Inositol and D-Chiro Inositol Treatment in Type 2 Diabetes

The Effectiveness of Myo-Inositol and D-Chiro Inositol Treatment in Type 2 Diabetes

  • Int J Endocrinol. 2016:2016:9132052. doi: 10.1155/2016/9132052.
Basilio Pintaudi 1 Giacoma Di Vieste 2 Matteo Bonomo 1
Affiliations

Affiliations

  • 1 Diabetes Unit, Niguarda Cà Granda Hospital, 20162 Milan, Italy.
  • 2 Diabetes Unit, Cantù Hospital, 20081 Abbiategrasso, Italy.
Abstract

Inositol has been used as a supplement in treating several pathologies such as PCOS, metabolic syndrome, and gestational diabetes. Both myo-inositol and its isomer d-chiro-inositol showed Insulin mimetic effects in conditions of Insulin resistance. Type 2 diabetes (T2DM) is a condition typically caused by Insulin resistance. There is a lack of evidence of inositol use in T2DM. We evaluated the effectiveness and safety of myo-inositol and d-chiro-inositol treatment in T2DM. This was a pilot study involving a consecutive sample of patients with T2DM with suboptimal glycemic control (HbA1c 7.0-10.0%) already treated with glucose-lowering agents. Patients (23.1% males, mean age of 60.8 ± 11.7 years) took for three months a combination of myo-inositol (550 mg) and d-chiro-inositol (13.8 mg) orally twice a day as add-on supplement to their glucose-lowering drugs. Possible occurrence of side effects was investigated. After three months of treatment fasting blood glucose (192.6 ± 60.2 versus 160.9 ± 36.4; p = 0.02) and HbA1c levels (8.6 ± 0.9 versus 7.7 ± 0.9; p = 0.02) significantly decreased compared to baseline. There was no significant difference in blood pressure, lipid profile, and BMI levels. None of the participants reported side effects. In conclusion, a supplementation with a combination of myo- and d-chiro-inositol is an effective and safe strategy for improving glycemic control in T2DM.

Figures
Products